Arphio partners with Colonis, improving access to medications for patients with rare diseases


Arphio is pleased to announce that we have partnered with UK based niche generics company Colonis to bring Rybrila, a rare indication drug to patients in need within several emerging market territories. 

Rybrila is an asset indicated in the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. 

Dr. Shlomo Sadoun, CEO at Arphio comments: “We are thrilled to be collaborating with Colonis,a key player in the UK, to bring treatments for rare diseases to patients in need. This collaboration exemplifies our commitment to improve access to medication for patients with rare diseases, as we continue to enhance our portfolio of innovative and effective treatment, within this segment.” 

Michael Dobson, Global Portfolio Director at Colonis comments: “Our mission is to provide access to medicines for patients who need them the most and we’re proud to expand our global partner network even further to make this rare indication drug available through our collaboration with Arphio . ”

About Arphio

Arphio is an orphan pharmaceutical company founded on the mission to improve patients access to vital treatments for rare diseases.

We believe that collaboration always yields the best results. That is why we are driven by the conviction that it is only by combining our expertise and global market reach with leading specialists in the development of orphan products that can we make vital treatments for rare diseases available to a broader population worldwide.

Arphio is founded by pharmaceutical professionals with expertise covering all major therapeutic areas and pharmaceutical forms. We are focused on rare disease detection, market access and the supply of orphan drugs internationally.

About Colonis 

Part of Clinigen, Colonis is a UK-based pharmaceutical company focusing on product licensing and commercialisation by bringing alternative formulations to market for patients with unmet clinical needs. In addition to its unlicensed to licensed capabilities, Colonis is dedicated to making medicines more manageable for patients and healthcare professionals.